Background
If the plan is considering allowing members who obtain specialty medications through a carve-out international sourcing program to bypass the Group Health Plan’s (GHP) prior authorization (PA) requirements, these considerations should be carefully weighed.
Importantly, the medication would remain covered under the GHP and would still require PA if obtained through the plan’s traditional pharmacy benefit. The proposed change would create two access pathways for the same medication:
- GHP pathway: Prior authorization required.
- International Sourcing pathway: Prior authorization waived.
The primary concern is not whether the medication is covered, but whether removing PA from one pathway eliminates important clinical safeguards that currently exist within the GHP.
Clinical Considerations
Prior authorization serves as more than a cost-management tool. For specialty medications, it is often the plan’s primary clinical review process before therapy begins.
A PA review may verify:
- The diagnosis supports the requested treatment.
- The members meet established clinical criteria.
- Appropriate first-line therapies have been considered or attempted.
- Significant drug interaction concerns are identified.
- Prescribing requirements are met when specialist oversight is expected.
- Dosing and administration are appropriate.
- Required monitoring, laboratory testing, or REMS (FDA Risk Evaluation & Mitigation Strategy) requirements are initiated.
If PA is waived, these functions do not necessarily disappear, but the plan should clearly identify who will perform them and how they will be documented.
Specialty Drugs Present Greater Clinical Risk
This issue is more significant for specialty medications than for traditional prescription drugs because specialty therapies frequently:
- Treat serious, chronic, rare, or life-threatening conditions.
- Require ongoing clinical monitoring.
- Carry higher risks of adverse events.
- Involve REMS requirements or other safety protocols.
- Depend on careful dosing and clinical oversight.
Removing PA eliminates one of the plan’s formal checkpoints designed to identify potential concerns before treatment begins.
Care Coordination and Visibility Concerns
When a medication is obtained outside the traditional pharmacy benefit, the plan may lose visibility into portions of the member’s treatment journey.
Potential concerns include:
- Incomplete pharmacy claim records.
- Reduced visibility into adherence and utilization patterns.
- Limited access to clinical information needed for care management.
- Reduced ability to identify drug interaction concerns across all medications.
- Less coordination among providers, pharmacies, and care management teams.
The degree of risk depends on the level of clinical integration between the international sourcing vendor, the PBM, providers, and the health plan. The key question is whether the alternative process provides the same level of clinical oversight and communication that currently exists through the PA process.
Accountability Considerations
If PA is removed, the plan should define the following in writing:
1.What clinical review replaces PA?
The question is who will perform a structured review comparable to the review currently conducted through the GHP.
Considerations include:
- What criteria are used?
- What data is reviewed?
- How are decisions documented?
- Is there an audit trail?
- How are safety concerns escalated?
2. Who is responsible for adverse outcomes?
If a member experiences a preventable adverse event related to a specialty medication obtained without PA, responsibility may become unclear.
Potential stakeholders include:
- The plan sponsor.
- Plan fiduciaries responsible for approving the benefit design.
- The prescribing provider.
- The international sourcing vendor.
Roles and responsibilities should be clearly documented before implementation.
Fiduciary Considerations
For self-funded ERISA plans, the primary fiduciary issue is prudence. The decision to remove PA should be supported by a documented evaluation demonstrating that:
- The clinical impact was considered.
- Alternative safeguards were reviewed.
- Accountability was established.
- The plan determined an alternative process.
- The plan determines the process adequately protects participants.
The concern is less about whether the decision produces a favorable outcome and more about whether the decision-making process was reasonable and well documented.
Plan Design Considerations
Allowing PA to apply under one access pathway but not another creates different utilization management standards for the same covered medication. While this does not appear to present a significant nondiscrimination concern in this structure, it does create a plan governance consideration because members may be subject to different clinical review processes depending on how the drug is obtained. The plan should document the rationale for the differing requirements.
MHPAEA Considerations
If any medications included within the international sourcing arrangement are used to treat mental health or substance use disorder conditions, the plan should evaluate whether the differing PA requirements create any Mental Health Parity and Addiction Equity Act (MHPAEA) nonquantitative treatment limitation (NQTL) concerns. A targeted parity review would be prudent before implementation.
Actions for Proceeding with a PA Waiver
At a minimum, the following actions are recommended:
- Document what clinical review process will replace PA.
- Define responsibility and accountability for clinical oversight.
- Confirm stop-loss carrier acceptance of the arrangement.
- Update plan documents and the SPD as necessary.
- Communicate the process and correlated risks with participants.
- Establish ongoing monitoring of clinical outcomes and utilization patterns.
- Periodically evaluate whether the alternative process is producing results comparable to the GHP’s PA program.
Risk Summary
| Issue | Risk Level | Primary Concern |
|---|---|---|
| Waiving PA for international sourcing | High | Loss of clinical safeguards, fragmented care, reduced visibility into treatment |
| Fiduciary decision-making | Moderate | Inadequate documentation of the rationale and review process |
| Plan governance | Moderate | Different clinical review requirements for the same covered drug |
| MPHPAEA (If Applicable) | Low-Moderate | Potential NQTL review considerations |
| Universal removal of PA under the GHP | High | Significant clinical, financial, and stop-loss exposure |
Conclusion
The primary risk of waiving PA within the international sourcing arrangement is not the loss of a utilization management requirement, it is the removal of a clinical review process that helps ensure specialty medications are prescribed, monitored, and managed appropriately. If the final decision is to waive PA, the key compliance and fiduciary questions become:
What clinical safeguards will replace the PA process, who will perform them, and how will accountability be documented?
Without clear answers to those questions, the plan assumes additional clinical, operational, and fiduciary risk in exchange for administrative convenience.
